Europe Botulinum Toxin Market Size, Share & Industry Trends Analysis Report By Product, By Application (Therapeutic and Aesthetic), By End User (Hospitals, Dermatology Clinics and Spas & Cosmetic Centers, By Country and Growth Forecast, 2022 - 2028

Europe Botulinum Toxin Market Size, Share & Industry Trends Analysis Report By Product, By Application (Therapeutic and Aesthetic), By End User (Hospitals, Dermatology Clinics and Spas & Cosmetic Centers, By Country and Growth Forecast, 2022 - 2028

The Europe Botulinum Toxin Market would witness market growth of 10.6% CAGR during the forecast period (2022-2028).

In order to inhibit the fusion of cholinergic vesicles with the cell membrane, the light (L) chain interacts with several proteins in the nerve terminals, including syntaxin, synaptosomal associated protein, or SNAP, and vesicle-associated membrane protein. After the injection, the paralytic effect peaks four to seven days later. Units of biological activity are the units used to express the dosage of all commercially produced botulinum toxins.

The computed median intraperitoneal lethal dose (LD50) for female Swiss-Webster mice is equal to one unit of botulinum toxin. The blocked neurotransmitter release is irreversible, yet the afflicted nerve terminals do not deteriorate. Nerve terminal sprouting and the development of new synaptic connections, which typically take two to three months, can restore function.

By preventing alpha motor neuron transmission at the neuromuscular junction, botulinum toxin causes striated muscle weakening. Its usage in disorders with excessive muscle activity, such as dystonia, is a result of this. Inhibiting transmission at gamma neurons within muscle spindles may change the overactivity of reflexes.

Acetylcholine is released at the presynaptic membrane of cholinergic neurons but is not released when the Clostridium botulinum toxin type A neurotoxin complex is present. In order to treat neuromuscular diseases, Botox was originally approved in the European Union by intramuscular injection. Botox for the treatment of axillary hyperhidrosis was proposed as a new indication through the Mutual Recognition Procedure (MRP) by the Marketing Authorization Holder, Allergan Pharmaceuticals (Ireland) Ltd.

The Germany market dominated the Europe Botulinum Toxin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $708.9 Million by 2028.The UK market is anticipated to grow at a CAGR of 9.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 11.4% during (2022 - 2028).

Based on Product, the market is segmented into Type A and Type B. Based on Application, the market is segmented into Therapeutic and Aesthetic. Based on End User, the market is segmented into Hospitals, Dermatology Clinics and Spas & Cosmetic Centers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Evolus, Inc. (Alphaeon Corporation), Merz Pharma GmbH & Co. KGaA, AbbVie, Inc., Ipsen Pharma, Galderma S.A., USWM, LLC, and Metabiologics, Inc. (Object Pharma).

Scope of the Study

Market Segments covered in the Report:

By Product

  • Type A
  • Type B
By Application
  • Therapeutic
  • Aesthetic
By End User
  • Hospitals
  • Dermatology Clinics
  • Spas & Cosmetic Centers
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Evolus, Inc. (Alphaeon Corporation)
  • Merz Pharma GmbH & Co. KGaA
  • AbbVie, Inc.
  • Ipsen Pharma
  • Galderma S.A.
  • USWM, LLC
  • Metabiologics, Inc. (Object Pharma)
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Botulinum Toxin Market, by Product
1.4.2 Europe Botulinum Toxin Market, by Application
1.4.3 Europe Botulinum Toxin Market, by End User
1.4.4 Europe Botulinum Toxin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Botulinum Toxin Market
Chapter 4. Europe Botulinum Toxin Market by Product
4.1 Europe Type A Market by Country
4.2 Europe Type B Market by Country
Chapter 5. Europe Botulinum Toxin Market by Application
5.1 Europe Therapeutic Market by Country
5.2 Europe Aesthetic Market by Country
Chapter 6. Europe Botulinum Toxin Market by End User
6.1 Europe Hospitals Market by Country
6.2 Europe Dermatology Clinics Market by Country
6.3 Europe Spas & Cosmetic Centers Market by Country
Chapter 7. Europe Botulinum Toxin Market by Country
7.1 Germany Botulinum Toxin Market
7.1.1 Germany Botulinum Toxin Market by Product
7.1.2 Germany Botulinum Toxin Market by Application
7.1.3 Germany Botulinum Toxin Market by End User
7.2 UK Botulinum Toxin Market
7.2.1 UK Botulinum Toxin Market by Product
7.2.2 UK Botulinum Toxin Market by Application
7.2.3 UK Botulinum Toxin Market by End User
7.3 France Botulinum Toxin Market
7.3.1 France Botulinum Toxin Market by Product
7.3.2 France Botulinum Toxin Market by Application
7.3.3 France Botulinum Toxin Market by End User
7.4 Russia Botulinum Toxin Market
7.4.1 Russia Botulinum Toxin Market by Product
7.4.2 Russia Botulinum Toxin Market by Application
7.4.3 Russia Botulinum Toxin Market by End User
7.5 Spain Botulinum Toxin Market
7.5.1 Spain Botulinum Toxin Market by Product
7.5.2 Spain Botulinum Toxin Market by Application
7.5.3 Spain Botulinum Toxin Market by End User
7.6 Italy Botulinum Toxin Market
7.6.1 Italy Botulinum Toxin Market by Product
7.6.2 Italy Botulinum Toxin Market by Application
7.6.3 Italy Botulinum Toxin Market by End User
7.7 Rest of Europe Botulinum Toxin Market
7.7.1 Rest of Europe Botulinum Toxin Market by Product
7.7.2 Rest of Europe Botulinum Toxin Market by Application
7.7.3 Rest of Europe Botulinum Toxin Market by End User
Chapter 8. Company Profiles
8.1 Evolus, Inc. (Alphaeon Corporation)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Approvals and Trials:
8.2 Merz Pharma GmbH & Co. KGaA
8.2.1 Company Overview
8.2.2 Recent strategies and developments:
8.2.2.1 Approvals and Trials:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.3.5.2 Approvals and Trials:
8.4 Ipsen Pharma
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 Galderma S.A.
8.5.1 Company Overview
8.5.2 Recent strategies and developments:
8.5.2.1 Geographical Expansions:
8.6 USWM, LLC
8.6.1 Company Overview
8.7 Metabiologics, Inc. (Object Pharma, Inc.)
8.7.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings